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Heavy drinkers are at risk for a spectrum of histologic alcohol-related liver injury: steatosis, 
alcoholic steatohepatitis (ASH), alcohol-related fibrosis, and cirrhosis. Alcoholic hepatitis 
(AH), the clinical entity associated with severe ASH, has high short-term mortality. The 
standard-of-care therapy, prednisolone, has limited efficacy and many side effects; no other 
treatment has consistently shown survival benefit. The National Institute on Alcohol Abuse 
and Alcoholism (NIAAA)-funded Alcoholic Hepatitis Consortia carry out translational 
research on pathophysiologic mechanisms, genetic and environmental risk factors, phase II 
clinical trials, and development of biomarkers. The consortia members were convened by the 
National Institutes of Health to address diagnostic criteria and practical issues related to 
clinical AH research, and to develop a set of common data elements to harmonize ongoing 
and future trials. This was accomplished through 3 face-to-face meetings of the investigators 
and representatives of the National Institutes of Health, and subsequent electronic 
communications over the course of 6 months. Evidence for the recommendations was based 
on published trials and observational data from several of the consortia members. A draft 
manuscript was iteratively reviewed by members of the consortia. The goal was to reach 
agreements on recommendations and definitions that could facilitate trial design, and 
simultaneously be tested by research groups pooling their data. The recommendations made 
here are specifically directed to achieve better uniformity in clinical trials, rather than 
serving as clinical practice guidelines.
Natural History of AH
Alcohol-related steatosis is the most common manifestation of heavy drinking. A “standard 
drink” in the United States (12 oz of beer, 5 oz of wine, or 1 oz of liquor) contains 14 g of 
alcohol; volunteers drinking approximately 10 drinks per day for 2–3 weeks consistently 
developed steatosis.1 This level of drinking, often for decades, is observed in AH,2,3 but only 
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a minority of such drinkers develop AH. The best established risk factors are female sex and 
increased body mass index; these and other factors have mainly been studied in the context 
of alcoholic liver disease (including steatosis and cirrhosis): nutritional deficiency, dietary 
composition (type of fat, caffeine), genetic factors (eg, PNPLA3 genotype), and smoking. 
Biopsy-documented AH has a 58% 4-year survival,2 with the worst outcomes in the first 
year in those with cirrhosis (35% survival).4 A Danish survey from 1999 to 20085 showed 
increasing 28-day (12%–15%) and 84-day (14%–24%) mortality rates, and a 5-year survival 
of 53% and 31% in those without and with cirrhosis, respectively.
Diagnostic Definition of AH
AH is a clinical entity with rapid onset of jaundice with elevated serum aspartate 
transaminase (AST), arising on the background of heavy alcohol use. Liver biopsy usually 
reveals ASH, cholestasis, and severe fibrosis The thresholds for amount and duration of 
alcohol use causing AH are not known, although an average consumption of more than 3 
drinks (~40 g) per day for women and 4 drinks (~50–60 g) per day for men are reasonable 
minimal thresholds for the diagnosis of AH. Patients typically have been drinking heavily 
for >5 years, but may be intermittently abstinent. For the diagnosis of AH, we expect that 
heavy alcohol use should have occurred for >6 months, with <60 days of abstinence before 
the onset of jaundice. Jaundice is often accompanied by malaise, tender hepatomegaly, and 
decompensation (ascites, encephalopathy, bacterial infection, and variceal bleeding). Serum 
bilirubin is usually elevated (>3 mg/dL [>50 μmol/L]), as is the AST (>50 IU/mL), and AST 
to alanine aminotransferase (ALT) ratio of >1.5. A review of a large series of patients seen 
by the consortium participants suggests that AST/ALT ratios of <1.5 are seen in <2% of 
patients with histologically proven AH. The AST and ALT do not typically exceed 400 
IU/mL, distinguishing AH from other liver diseases such as drug-induced liver injury (DILI) 
and ischemic hepatitis. Imaging should exclude biliary obstruction, and viral hepatitis, 
severe autoimmune liver disease, and Wilson disease should be tested for.
Liver biopsy can be useful in confirming the diagnosis and has prognostic value.6 Of 
patients with a clinical diagnosis of AH, 10–20% may have other liver diseases found only 
by biopsy or may not have histologic ASH.7 The histologic hallmarks of ASH include 
macrovesicular steatosis, with ≥ 1 of the following: neutrophil infiltration, hepatocyte injury 
(ballooning), and Mallory-Denk bodies, although this is an area in which the expertise of 
pathologists is needed. The presence of megamitochondria, satellitosis (neutrophils 
surrounding dying/dead hepatocytes), and cholestasis (bilirubinostasis) is common, and may 
relate to prognosis.8 Fibrosis is always present, following a “chicken-wire” pattern; the 
majority of patients with severe AH have cirrhosis. Some patients with ASH do not have 
clinical AH; this asymptomatic AH (“walking AH”) may coexist with cirrhosis in as many 
as 30%–40%,9 and may progress to clinical AH. An important research question is how to 
identify and intervene in patients with walking AH. Patients with undiagnosed cirrhosis may 
decompensate owing to superimposed AH, that is, acute-on-chronic liver failure. Limitations 
of biopsy include sampling variability, lack of well-validated histologic grading systems for 
necroinflammatory features, unavailability of transjugular liver biopsy at some sites, and 
risks and costs of the procedure.
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AH Clinical Trials: Inclusion and Exclusion Criteria and Outcomes
Inclusion Criteria
We recommend the following inclusion criteria for clinical studies (Table 1). However, we 
recognize that biopsy may not be feasible in all situations. Thus, liver biopsy confirmation of 
ASH should be required only for patients with clinical AH classified as possible AH (see 
below).
1. Definite AH: Clinically diagnosed and biopsy proven. In the future, imaging 
techniques and biomarkers may replace liver biopsy for definite diagnosis of AH. 
However, biopsy may have a role in determining molecular pathways that 
identify the mechanism of injury in AH and inform the choice of therapy.
2. Probable AH: Clinically diagnosed AH without confounding factors (see below). 
In patients with heavy alcohol use and typical liver tests; and negative markers 
for immune (antinuclear antibody < 1:160 or anti–smooth antibody < 1:80 
dilutions) and metabolic liver disease; and absence of sepsis, shock, cocaine use, 
or recent use of a drug with DILI potential within 30 days, a diagnosis other than 
AH will be made in <10% of patients on liver biopsy. Patients with positive tests 
for chronic hepatitis C (HCV), B, or non-alcoholic steatohepatitis do not 
commonly present in a fashion mimicking AH. Therefore, a biopsy is not 
essential for inclusion of these cases of probable AH in research studies. The 
potential misclassification of these subjects without histologic confirmation 
should be accounted for in calculating the sample sizes.6
3. Possible AH: Clinically diagnosed but with potential confounding factors, 
including possible ischemic hepatitis (eg, severe upper gastrointestinal [UGI] 
bleed, hypotension, or cocaine use within 7 days); possible DILI; uncertain 
alcohol use assessment (eg, patient denies excessive alcohol use); and atypical 
laboratory tests (eg, AST < 50 IU/mL or > 400 IU/mL, AST/ALT ratio < 1.5), 
antinuclear antibody > 1:160 or SMA > 1:80 We recommend that these patients 
undergo biopsy for confirmation of AH.
Stratification Based on Severity
It is important to stratify AH patients by disease severity. Short-term mortality can be 
predicted using the Maddrey discriminant function, Model for End-Stage Liver Disease 
(MELD) score, Age-Bilirubin-International Normalized Ratio- Creatinine score, and 
Glasgow Alcoholic Hepatitis Scores. Patients with severe AH defined by a Maddrey 
discriminant function of ≥32 have a 1-month morality rate as high as 20%–50%, so the 30-
day survival was the endpoint for most trials. A MELD score of >20 was suggested as an 
inclusion criterion10 because it predicts a 90-day mortality of 20%. Failure of improvement 
in serum bilirubin (the Lille score) predicts patients with severe AH who are unlikely to 
benefit from continued corticosteroid therapy. The best predictor of survival may be a 
combination of the MELD and Lille scores,11 although it is not known whether the Lille 
score will apply to novel therapies.
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Patients with a Maddrey discriminant function of <32 were usually excluded from trials 
because their expected 30-day survival is >90% with supportive care; however, up to 5%–
10% of these patients may decompensate and die in the next 6 months. This cohort of 
patients may be suitable for early phase studies of novel compounds. Recent trials with 
longer follow-up times noted complications developing between 30 and 90 days after 
stopping steroids, with mortality rates at 90 days that were no different from those given 
supportive therapy.3 Thus, we recommend that future trials be designed with primary 
outcomes beyond 30-day mortality. Additional factors which contribute to medium term (≤1 
year) mortality are not assessed by the Maddrey discriminant function and MELD scores, 
that is, different degrees of fibrosis. Although cirrhosis is often evident from imaging and 
other studies, the extent of fibrosis is difficult to quantify without biopsy, and for ethical 
reasons repeated biopsies have not been performed. Magnetic resonance elastography or 
Fibroscan (in patients without ascites) may allow better prognostication.
Assessing predictors of mortality beyond one year is difficult, as the main determinants are 
the presence of cirrhosis and persistent drinking12 and there were no histologic features on 
liver biopsy that correlated with long-term prognosis13; certainly, the maintenance of 
abstinence should be a high priority in clinical care and used as a metric in future clinical 
trials.
Exclusion Criteria
Subjects with a MELD score of >30 or a Maddrey discriminant function of >60 have such a 
poor prognosis that they should be stratified separately and excluded from phase I and II 
studies, testing the safety and proof of concept of molecules on AH-induced liver injury, 
respectively; power calculations need to be adjusted accordingly. The MELD-Lille scores 
might be used to further stratify patients into those with very high mortality and those with 
such high mortality that liver support approaches or urgent transplantation should be 
considered, rather than pharmacotherapy. Heavy alcohol consumption accelerates the 
development of cirrhosis in patients with chronic hepatitis C virus and 
hemochromatosis.14,15 How these disorders alter the course or response to treatment of AH 
is unknown, although many patients with hepatitis C virus were likely included in earlier 
trials.16 The exclusion of patients with other liver diseases may improve homogeneity, but 
overlook potential benefit for those with multiple diagnoses. Because nonalcoholic 
steatohepatitis does not cause a syndrome similar to AH, and obesity is a risk factor for 
alcoholic liver disease,17 overweight patients who are drinking heavily should be eligible for 
AH clinical trials.
Up to 70% of patients with AH have the systemic inflammatory syndrome,18 in one-half of 
whom no infection is identifiable. Thus, a systemic inflammatory syndrome at admission 
should not be an exclusion criterion. Criteria defining infections in cirrhotic patients were 
recently published, and seem appropriate for AH,19 both for exclusion from trials or as a 
reportable complication (below). Patients with infection not associated with multiorgan 
failure can be considered for inclusion once the infection is controlled. Patients with 
uncontrolled infection are at increased risk for multiorgan failure with a high mortality 
rate18; patients with multiorgan failure at diagnosis should be excluded or stratified. Criteria 
CRABB et al. Page 5
Gastroenterology. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
for grading multiorgan failure in patients with cirrhosis have been proposed20 and may be 
useful for AH research.
Overt UGI bleeding is an exclusion criterion in the majority of trials, although retrospective 
studies suggest that patients whose bleeding is controlled have similar survival to patients 
without bleeding. Thus, recent UGI bleeding that is controlled for >48 hours should not 
exclude the patient.
Acute kidney injury or hepatorenal syndrome at presentation of AH is especially worrisome, 
owing to the high probability of progression. Usually patients with creatinine of >2.5 mg/dL 
are excluded, but could be considered for trials targeting concomitant kidney injury. Other 
exclusion criteria may include other underlying chronic liver diseases (active hepatitis B, 
chronic hepatitis C, hemochromatosis, autoimmune liver disease, Wilson disease, suspected 
DILI), underlying hepatic and extrahepatic malignancies, and disorders potentially worsened 
by immunosuppressants (latent tuberculosis), but this exclusion may not apply to 
nonimmunosuppressive treatments. Uncontrolled drug addiction is commonly an exclusion 
criteria for clinical trials, and is more common in the AH population.
Outcomes
A 90-day mortality endpoint is preferred to the traditional 30-day mortality in light of recent 
trials. In addition to mortality, endpoints that reflect improvements in liver function (eg, 
change in Maddrey discriminant function or MELD score) should be considered for the less 
severely ill group of patients with AH. There is no instrument currently available that 
measures disease-specific quality of life in AH. Measures of functional status and quality of 
life; well-being (eg, WHO Performance status or EQ5D); presence or absence of 
complications of chronic liver disease such as ascites, infection, acute kidney injury, and 
encephalopathy; days of hospitalization; work productivity; use of medical resources, 
including liver transplantation; and abstinence rates after discharge may be used as 
important outcomes.
Recommended Common Datasets for Patients in Clinical Trials for AH: 
Endpoints, Outcomes, and Adverse Events
Suggested common datasets for patients in clinical trials are listed in Table 2: they include 
usual blood tests for severe liver injury, potential risk factors for AH, and measures related to 
alcohol consumption before and after the onset of AH. The timing of these measurements 
will vary between the short term (the traditional measures) and longer term, depending on 
the outcomes defined (late deaths, complications of cirrhosis). Adverse events include the 
usual complications of severe liver disease (Table 3), and those that might be caused by 
treatments; it may be difficult to separate these. Better tools and reliable surrogate markers 
to characterize the heterogeneous population of patients with AH will facilitate phase II and 
III studies evaluating new treatments.6
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Common Data Elements for Capturing and Reporting Adverse Events
All clinical trials use standard data elements such that safety of the tested compound is 
rigorously investigated. Requirements for safe conduct and reporting results of human 
research in the United States are dictated by the Code of Federal Regulation (CFR) Title 21. 
These include (1) drug trial having an investigational new drug approval from the Food and 
Drug Administration (FDA); (2) registration on Clinicaltrials.gov; (3) adherence to the 
principles of good clinical practices; (4) having a clinical trial monitoring plan; (5) having a 
data and safety monitoring plan in place before their initiation; and (6) storage of clinical 
trial data in compliance with 21CFR312.
Adverse events, treatment emergent adverse events, serious adverse events, sudden and 
unexpected serious adverse reactions, and fatalities should be defined, captured, and 
reported in a predefined fashion. General guidelines are contained in 21CFR312.32. The 
reporting requirements vary depending on the nature of the adverse event and different 
regulatory and institutional stakeholders. In the United States, these include the FDA, local 
institutional review board, Data Safety and Monitoring Board, funding agency, sponsor (if 
applicable), and other participating sites. It is important to have well thought out reporting 
schemata before initiating the clinical trials and predefined “events of interests” for 
standardizing study data across various consortia undertaking observational cohort studies. 
We suggest that the following are the most important events of interest for patients with AH 
(Table 3):
1. Acute kidney injury;
2. UGI bleeding (variceal or nonvariceal);
3. Hepatic encephalopathy;
4. Infections (spontaneous or secondary bacterial peritonitis, urinary tract infection, 
pneumonia, cellulitis, infectious diarrhea including Clostridium difficile 
infection, or intraabdominal infections, positive blood cultures);
5. Diuretic-resistant ascites; and
6. Unexpected elevation of liver enzymes, i.e., development of DILI (this may 
require independent adjudication, as is done for DILI in other clinical trials).
In conclusion, these recommendations from the NIAAA Alcoholic Hepatitis consortia 
outline a framework for clinical research in AH. Its purpose is to provide consensus-based 
recommendations regarding definitions, clinical trial design, minimal datasets, and the 
reporting and monitoring of adverse events. This is a first step toward data standardization 
for all variables commonly used in translational, clinical, and observational studies of AH 
that will facilitate data sharing and comparisons across studies, increasing the efficiency and 
effectiveness of AH research. We anticipate that ongoing research will help provide 
improved evidence for the definition of AH (eg, thresholds of alcohol use, use of other 
surrogates of heavy use besides self-report, thresholds of transaminase and bilirubin levels, 
better understanding of “walking AH” and its natural history). Writing this statement has 
brought such questions into sharper focus.
CRABB et al. Page 7
Gastroenterology. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Despite significant progress in our understanding of the pathophysiology of alcoholic liver 
disease, relatively few clinical trials in AH have been conducted, and there has been little 
improvement in outcome. Clinical Trials.gov lists only 4 interventional trials currently 
recruiting for AH patients in the United States; an additional 11 are cited from other 
countries. Research in AH is a challenging task given its heterogeneity, high mortality rate, 
the complexity of interacting pathophysiologic mechanisms, and the difficulties of recruiting 
and retaining patients with alcohol use disorders. All these factors contribute to the 
difficulties in designing, conducting, and interpreting clinical studies. The clinical diagnosis, 
staging, and prognostic assessment of AH patients has been inconsistent, making the meta-
analysis of trials difficult. Thus, there is an urgent need to adopt standardized approaches 
and vocabulary for diagnostic criteria and for data collection and reporting.
The development of data standards and common data elements is a continuous process 
requiring input from many stakeholders at each stage. The current report is a starting point 
that will necessarily evolve to improve clarity and utility. To promote the implementation of 
these standardized data elements and measures, their use is encouraged by all future 
NIAAA-funded research projects in AH and feedback is solicited from the broader 
community that deals with AH, which may be directed to Dr Svetlana Radaeva at the 
NIAAA (sradaeva@mail.nih.gov). Future steps will include (1) the development in 
collaboration with FDA of clearly defined and measurable surrogate endpoints and new 
definitions of clinical benefits for the evaluation of drug efficacy and (2) standardization of 
data exchange in clinical research studies and patient care activities to create a strong data 
interchange environment and provide new opportunities to conduct cost-effective, large-
scale observational studies. These efforts should improve data sharing across institutions and 
studies and improve clinical practice guidelines for the diagnosis and management of AH.
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Table 1
Inclusion and exclusion criteria for clinical trials in alcoholic hepatitis
Inclusion Criteria
◦ Onset of jaundice within prior 8 weeks
◦ Ongoing consumption of > 40 (female) or 60 (males) g alcohol/day for 6 months or more, with less than 60 days of abstinence before 
the onset of jaundice
◦ Aspartate aminotransferase > 50, aspartate aminotransferase/alanine aminotransferase > 1.5, and both values < 400 IU/L
◦ Serum bilirubin (total) > 3.0 mg/dL
◦ Liver biopsy confirmation in patients with confounding factors
Stratification based on severity
◦ Maddrey’s discriminant function ≥ 32 assuming a control prothrombin time of 12 seconds
◦ Model for End-stage Liver Disease score > 20
◦ Less ill patients may be appropriate for early phase or mechanistic studies
Exclusion criteria
◦ Patients with very severe disease (Maddrey discriminant function > 60 or Model for End-stage Liver Disease score > 30) may need to 
be excluded from some studies
◦ Uncontrolled infections
◦ Multiorgan failure
◦ Uncontrolled upper gastrointestinal bleeding
◦ Preexisting kidney injury with serum creatinine > 2.5 mg/dL
◦ Other underlying liver diseases including hepatitis B infection,* autoimmune liver diseases, Wilson disease, suspected drug-induced 
liver injury*
◦ Hepatocellular carcinoma or other active malignancies except skin cancer
◦ Pregnancy
◦ Underlying diseases that might be exacerbated by proposed treatments (eg, hepatitis C,a hemochromatosis, latent tuberculosis)
◦ Uncontrolled drug addiction
a
Exclusion of patients with hepatitis B, hepatitis C, or human immunodeficiency virus infection or hemochromatosis is a subject of controversy, 
and may depend on the mechanism of action of the treatment under study.
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Table 2
Common Clinical Datasets
Type of Data Included
Demographic information Age, sex, racial identity, socioeconomic status, occupation, marital status, education, family/friend contact
Alcohol consumption data Age at onset of drinking, estimated levels of consumption (expressed as g/d), patterns of recent drinking (time line 
follow-back), preferred beverages, frequency of binge drinking, prior attempts to stop drinking use of medications 
to reduce drinking, family history of alcohol abuse and liver disease, history of recurrent alcoholic hepatitis with 
relapse to drinking
General clinical data Standard liver tests (aspartate aminotransferase, alanine aminotransferase, bilirubin, international normalized ratio 
(INR), albumin, total protein); presence or development of encephalopathy or gastrointestinal bleeding, renal 
function (estimated GFR, creatinine, electrolytes), measures of metabolic syndrome (high-density lipoprotein 
cholesterol, cholesterol, triglyceride, low-density lipoprotein cholesterol, hemoglobin A1c); medications 
(including over-the-counter medications, herbals, dietary supplements, and probiotics); hepatitis B virus, hepatitis 
C virus, human immunodeficiency virus serology; antinuclear antibody; iron, ferritin, iron binding capacity; Lille 
score if steroids used
Measures of social stress Other behavioral disorders (dual diagnoses—depression, anxiety, posttraumatic stress disorder), socioeconomic 
stress (eg, scales from the Health and Retirement Study); smoking, use of other drugs of abuse (eg, cocaine)
Nutritional Recent weight change, ability to consume a nutritious diet after the diagnosis of alcoholic hepatitis is made, survey 
of nutritional status, caffeine use (coffee, tea), cooking oil preference, nut consumption
Biobanking Whole blood, plasma/serum, urine, peripheral blood mononuclear cells, stool (bulk stool or mucosal swab), DNA, 
annotation about nutritional state (fed or fasting) when samples obtained.
Patient outcomes 30- and 90-day survival, work productivity, well-being, quality of life, World Health Organization Performance 
status, EQ5D, abstinence rates after discharge
Health economics data Cost of care (including acute hospital care and post-discharge care for alcohol addiction), length of hospital stay
NOTE. Some of these measures will only need to be obtained once (eg, family history, racial identity, education, DNA sample); others need to be 
tracked over time (eg, diet, alcohol use, medications, and illicit drugs).
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Table 3
Endpoints, Outcomes, and Adverse Events
1 Early endpoints: 30-day mortality, resolution of systemic inflammatory response syndrome, development of organ system failure 
(lungs, kidneys, gastrointestinal bleeding, encephalopathy, infection), change in Maddrey discriminant function and Model for 
End-stage Liver Disease, and Lille score, change in bilirubina
2 Later endpoints: 3-, 6-, and 12-month survival, liver decompensation (including infections)
3 Adverse events:
a. Usual adverse events tracked in all clinical trials (bone marrow/blood cells, renal, skin, central nervous system, 
pulmonary, infections)
b. Additional adverse events related to the class of drug being tested
c. Adverse events typically associated with decompensated cirrhosis or severe alcoholic hepatitis: worsening renal 
function, GI bleeding (usually upper), worsening liver synthetic and injury tests, encephalopathy, hyponatremia, 
ascites, hypotension, edema, spontaneous bacterial peritonitis, other infections.
a
The development of surrogate markers of improvement or worsening aside from usual clinical measures is much needed.
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